Fulgent Genetics, Inc. (FLGT)
| Market Cap | 453.27M -22.8% |
| Revenue (ttm) | 320.35M +9.5% |
| Net Income | -73.81M |
| EPS | -2.40 |
| Shares Out | 28.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,800 |
| Open | 14.97 |
| Previous Close | 15.11 |
| Day's Range | 14.94 - 15.97 |
| 52-Week Range | 13.46 - 31.04 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 22.50 (+40.98%) |
| Earnings Date | May 1, 2026 |
About FLGT
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he... [Read more]
Financial Performance
In 2025, Fulgent Genetics's revenue was $322.67 million, an increase of 13.83% compared to the previous year's $283.47 million. Losses were -$60.51 million, 41.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price target is $22.5, which is an increase of 40.98% from the latest price.
News
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Com...
Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler
Piper Sandler lowered the firm’s price target on Fulgent Genetics (FLGT) to $15 from $30 following quarterly results. The firm keeps a Neutral rating on the shares. Published first on
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Fulgent Genetics Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined due to a major customer transition, but acquisitions and new product launches are expected to drive growth. Guidance for 2026 is reaffirmed, with improved margins and reduced customer concentration risk anticipated.
Fulgent Genetics reports Q1 EPS (36c) vs 4c last year
Reports Q1 revenue $71.1M vs $73.5M last year. Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “I am encouraged by our first quarter performance and
Fulgent Reports First Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development busi...
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fulgent Genetics, Inc. (“Fulgent" or the "Company") (NASDAQ:FLGT) investors that the firm has initiated an investigation in...
Fulgent Genetics price target lowered to $22 from $35 at UBS
UBS lowered the firm’s price target on Fulgent Genetics (FLGT) to $22 from $35 and keeps a Buy rating on the shares.
Fulgent Genetics Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $322.7M, with strong gains in precision diagnostics and anatomic pathology. 2026 guidance anticipates $350M revenue, offsetting a major customer loss with acquisitions and continued AI-driven efficiency.
Fulgent Genetics reports Q4 EPS 16c, consensus 3c
Reports Q4 revenue $83.34M, consensus $85.38M. Ming Hsieh, chairman and CEO, said, “I am pleased with the progress we made in 2025 as we delivered on our strategic and product
Fulgent Genetics sees FY26 EPS ($1.45), consensus (32c)
Sees FY26 revenue $350M, consensus $356.29M. Sees FY26 cash, cash equivalents, restricted cash, and investments in marketable securities of approximately $685M. Paul Kim, CFO, said, “In 2025, we demon...
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics to acquire Bako Diagnostics and StrataDx
Fulgent Genetics (FLGT) “announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a premier pathology laboratory headquartered in Alpharetta, GA and to...
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development busi...
Fulgent Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference
Consistent organic growth, technology-driven efficiency, and a robust cash position support ongoing expansion in diagnostics and therapeutics. Key catalysts include new product launches, AI integration, and upcoming clinical milestones in oncology.
Fulgent Genetics price target raised to $30 from $21 at Piper Sandler
Piper Sandler raised the firm’s price target on Fulgent Genetics (FLGT) to $30 from $21 and keeps a Neutral rating on the shares. The firm cites the company’s quarterly results
Fulgent Genetics Transcript: UBS Global Healthcare Conference 2025
Revenue and margins exceeded expectations, with strong growth in precision diagnostics and biopharma services. Technology integration, digital pathology, and AI are driving operational gains, while expanded managed care contracts and new product launches position the business for continued growth. M&A and therapeutics development remain strategic priorities.
Fulgent to Participate in Upcoming Conferences
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Genetics Earnings Call Transcript: Q3 2025
Q3 2025 saw sequential and year-over-year growth, with revenue reaching $84.1 million and improved margins. Full-year guidance was raised, driven by strong performance in precision diagnostics, new product launches, and progress in the therapeutic pipeline.
Fulgent Genetics reports Q3 EPS (21c), consensus (22c)
Reports Q3 revenue $84.07M, consensus $81.43M. Ming Hsieh, Chairperson of the Board of Directors and Chief Executive Officer, said, “We continued to build momentum in our laboratory services business ...